Plasma-lit 148 Aqueous Solution (Plasma-Lyte 148 Solution in Water)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substancePotassium Chloride + Magnesium Chloride + Sodium Acetate + Sodium Gluconate + Sodium ChloridePotassium Chloride + Magnesium Chloride + Sodium Acetate + Sodium Gluconate + Sodium Chloride
Similar drugsTo uncover
  • Plasma-lit 148 Aqueous Solution
    solution in / in 
    Baxter Helskea Limited     United Kingdom
    • Dosage form: & nbspSolution for infusions
    Composition:

    In 1000 ml contains:

    Sodium chloride 5.26 g; sodium gluconate - 5.02 g; sodium acetate - 3.68 g; potassium chloride 370 mg; magnesium chloride 300 mg.

    Ionic composition:

    Sodium ion -140 mmol Potassium ion 5.0 mg Magnesium ion -1.5 mmol Chlorine ion 98 mmol Acetate ion 27 mmol Gluconate ion 23 mmol

    Description:Colorless transparent liquid.
    Pharmacotherapeutic group:Plasmasuberant
    ATX: & nbsp

    B.05.B.B.01   Electrolytes

    Pharmacodynamics:

    Plasma-Lit 148 the aqueous solution corrects the acid-base state, replenishes the deficiency of fluid and electrolytes, increases diuresis, has an antiaggregant property, reduces metabolic acidosis, improves microcirculation, exerts detoxification, antishock action

    Indications:

    Plasma-lit 148 aqueous solution is used in adults and children as a component of infusion therapy in complex treatment of shock; thermal trauma and acute blood loss; hypotonic and isotonic forms of hypohydration and metabolic acidosis in severe patients; forcorrection of water-salt balance in acute diffuse peritonitis and intestinal obstruction; for the treatment of patients with intestinal fistula; at decompensation of electrolyte disturbances; in patients with acute intestinal infections; with dehydration and metabolic acidosis. The volemic effect of the drug is short, in the treatment of severe hypovolemia, a combination with colloidal solutions as well as blood and its components is recommended.

    Contraindications:

    Alkalosis, essential hypertensionYeghidraining, as well as cases where the introduction of large volumes of liquid is contraindicated.

    Carefully:not described
    Pregnancy and lactation:not described
    Dosing and Administration:

    The drug is used under the control of laboratory studies.

    Apply intravenously (struino and drip). Before administration, the solution is warmed to body temperature.

    The daily dose for adults is 5-20 ml / kg, if necessary, can be increased to 30-40 ml / kg. Entering at a speed of 60-80 drops per minute, an inkjet injection is allowed. The daily dose for children is 5-10 ml / kg, the rate of administration is 30-60 drops per minute. The course of treatment is 3-5 days.

    Side effects:

    Perhaps the development of hyperkalemia.There may be venous irritation and thrombophlebitis at the injection site.

    Overdose:not described
    Interaction:not described
    Special instructions:

    In patients with renal, cardiac or liver failure, it is necessary to monitor the level of electrolytes in the plasma.

    It is recommended to replace all devices for intravenous infusion at least once a day. A careful and aseptic mixing of additional substances is necessary. After mixing, the solution, if not injected immediately, stored at a temperature of 2 to 8 C for 24 hours.

    Do not inject a cloudy solution or from a damaged container.

    Effect on the ability to drive transp. cf. and fur:not described
    Form release / dosage:For 500 ml or 1000 ml in plastic containers of the "Viflex" type. Each container is packed in a sealed transparent plastic bag. For 10 1000 ml containers, 20 containers of 500 ml each in a cardboard box.
    Packaging:plastic containers made of PVC "Vifaflex" (1) - plastic bags
    plastic containers made of PVC "Vifaflex" (1) - plastic bags (10)
    plastic containers made of PVC "Vifaflex" (1) -mesh plastic bags (20)
    Storage conditions:

    At temperatures up to 25 ° ะก. Do not freeze. Keep out of the reach of children.

    Shelf life:

    2 years. The drug should be used before the date indicated on the package

    Terms of leave from pharmacies:On prescription
    Registration number:P N014661 / 01-2002
    Date of registration:23.01.2009
    The owner of the registration certificate:Baxter Helskea LimitedBaxter Helskea Limited United Kingdom
    Manufacturer: & nbsp
    Representation: & nbspBaxter Baxter USA
    Illustrated instructions
      Instructions
      Up